This study compares the effect of Montelukast vs Placebo on Flow Mediated Dilatation of the Brachial Artery (FMD) in patients with obstructive sleep apnea syndrome.
Obstructive Sleep Apnea Syndrome (OSAS) induces low-grade systemic and vascular inflammation, including activation of the leukotriene pathway. In apneic patients, the urinary excretion of LTE4, a systemic marker of CysLT pathway activation, is increased in relation to the severity of OSAS and it's an independent predictor of cardiovascular risk event occurring at 10 years. Montelukast is a CysLT1 receptor antagonist. By blocking CysLT1 receptors, montelukast prevents vasoconstriction, proliferation and migration of smooth muscle cells, adhesion molecule expression, and leukocyte recruitment induced by CysLTs.Montelukast may improve endothelial function and reduce vascular remodeling in apneic patients. A pharmacological blockade of CysLT pathway would be an interesting therapeutic strategy to limit the cardiovascular consequences of OSAS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1
The capsules will be presented in box of 95 capsules packaged in unit blister
Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
University Hospital
Bron, France
Métropole Savoie Hospital
Chambéry, France
University Hospital
Clermont-Ferrand, France
University Hospital Grenoble
Grenoble, France
Change in FMD of the brachial artery between the beginning and end of each treatment period (Montelukast and placebo), expressed as absolute value (FMD unit is %) and measured in a standardized manner.
Time frame: before and after 3 months treatment
Concentrations of urinary LTE4 at the beginning and end of each treatment period
Time frame: before and after 3 months the two periods of treatment
24h ambulatory blood pressure (systolic and diastolic) measurement
Time frame: before and after 3 months of the two periods of treatment, and 15 days after the last period
Polysomnography at inclusion and at the end of each treatment period
Time frame: inclusion and at the end of the two periods of treatment
Plasma concentration of Montelukast measured by HPLC-MS at the end of the Montelukast treatment period
Time frame: at the end of Montelukast treatment period
Collection of adverse events
Time frame: from inclusion to 15 days after the last period of treatment
Comparison of Cardiovascular Events occurence (myocardial infarction, Stroke, Cardiovascular Death) between the two periods
Time frame: from inclusion to 15 days after the last period of treatment
Concentrations of plasma CRPus at baseline and at the beginning and end of each treatment period
Time frame: before and after 3 months the two periods of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital
Grenoble, France
Annecy Genevois Hospital
Metz-Tessy, France
University Hospital
Pierre-Bénite, France
University Hospital
Saint-Etienne, France